Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis.

ABSTRACT:

Introduction

The use of renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), was alleged to cause a more severe course of novel coronavirus disease 2019 (COVID-19).

Methods

We systematically reviewed the published studies to assess the association of RAS inhibitors with mortality as well as disease severity in COVID-19 patients. A systematic literature search was performed to retrieve relevant original studies investigating mortality and severity (severe/critical disease) in COVID-19 patients with and without exposure to RAS inhibitors.

Results

A total of 59 original studies were included for qualitative synthesis. Twenty-four studies that reported adjusted effect sizes (24 stud

SUBMITTER: Hasan SS 

PROVIDER: S-EPMC7486167 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature